{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:46:54Z","timestamp":1782776814860,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.dld.2026.04.018","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:21:55Z","timestamp":1779103315000},"page":"911-918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunomodulatory therapies and emerging drug associations with microscopic colitis: A global pharmacovigilance analysis"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6397-0941","authenticated-orcid":false,"given":"Yaron","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"M\u00fcnch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1235-1927","authenticated-orcid":false,"given":"Asaf","family":"Levartovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-6338","authenticated-orcid":false,"given":"Chen","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8191-055X","authenticated-orcid":false,"given":"Maya","family":"Fischman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-9832","authenticated-orcid":false,"given":"Tal","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-100X","authenticated-orcid":false,"given":"Adam","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dld.2026.04.018_bib0001","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.2003.023440","article-title":"Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients","volume":"53","author":"Olesen","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.04.018_bib0002","doi-asserted-by":"crossref","unstructured":"Bohr J, Tysk C, Eriksson S, Abrahamsson H, Jamerot G. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. vol. 39. 1996.","DOI":"10.1136\/gut.39.6.846"},{"issue":"12","key":"10.1016\/j.dld.2026.04.018_bib0003","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ecco-jcc\/jjaa108","article-title":"Incidence and prevalence of microscopic colitis between 2001 and 2016: a Danish nationwide cohort study","volume":"14","author":"Weimers","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.dld.2026.04.018_bib0004","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/gut.36.6.880","article-title":"Microscopic colitis syndrome","volume":"36","author":"Veress","year":"1995","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.dld.2026.04.018_bib0005","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1572-0241.1999.00870.x","article-title":"Incidence of collagenous and lymphocytic colitis: a 5-year population-based study","volume":"94","author":"Fern\u00e1ndez-Ba\u00f1ares","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.04.018_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00273-2","article-title":"Microscopic colitis","author":"Burke","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.dld.2026.04.018_bib0007","first-page":"281","article-title":"The association between microscopic colitis and celiac disease: a systematic review and meta-analysis","volume":"35","author":"Nimri","year":"2022","journal-title":"Ann Gastroenterol"},{"issue":"11\u201312","key":"10.1016\/j.dld.2026.04.018_bib0008","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/apt.16614","article-title":"Autoimmune diseases in microscopic colitis: a Danish nationwide case\u2013control study","volume":"54","author":"Wildt","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2026.04.018_bib0009","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/apt.14916","article-title":"Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study","volume":"48","author":"Bonderup","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dld.2026.04.018_bib0010","article-title":"Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs","volume":"110","author":"Masclee","year":"2015","journal-title":"Off J Am Coll Gastroenterol | ACG"},{"issue":"10","key":"10.1016\/j.dld.2026.04.018_bib0011","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/MIB.0000000000000143","article-title":"Drug exposure and risk of microscopic colitis: a nationwide Danish case\u2013Control study with 5751 cases","volume":"20","author":"Bonderup","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.dld.2026.04.018_bib0012","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ibd\/izy240","article-title":"Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity?","volume":"25","author":"Choi","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"16","key":"10.1016\/j.dld.2026.04.018_bib0013","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3748\/wjg.v18.i16.1871","article-title":"Colitis associated with biological agents","volume":"18","author":"Freeman","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2026.04.018_bib0014","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.04.018_bib0015","series-title":"FDA adverse event reporting system (FAERS) public dashboard","year":"2022"},{"issue":"4","key":"10.1016\/j.dld.2026.04.018_bib0016","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ueg2.12736","article-title":"Gastrointestinal perforations associated with JAK inhibitors: a disproportionality analysis of the FDA adverse event Reporting System","volume":"13","author":"Goldman","year":"2025","journal-title":"United Eur. Gastroenterol J"},{"key":"10.1016\/j.dld.2026.04.018_bib0017","series-title":"Data mining applications in engineering and medicine","article-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS)","author":"Poluzzi","year":"2012"},{"key":"10.1016\/j.dld.2026.04.018_bib0018","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS PV): development and statement","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.dld.2026.04.018_bib0019","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.dld.2026.04.018_bib0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.dld.2026.04.018_bib0021","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2026.04.018_bib0022","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.dld.2026.04.018_bib0023","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","article-title":"An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series","volume":"76","author":"Varkas","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.dld.2026.04.018_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis or psoriasiform exanthemata","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.dld.2026.04.018_bib0025","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1002\/ibd.22963","article-title":"Rituximab-associated colitis","volume":"19","author":"Bhalme","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.dld.2026.04.018_bib0026","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/00365521.2017.1280530","article-title":"Rituximab-induced Crohn\u2019s disease","volume":"52","author":"Varma","year":"2017","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"10.1016\/j.dld.2026.04.018_bib0027","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/13524585231195854","article-title":"Immune-mediated colitis associated with ocrelizumab: a new safety risk","volume":"29","author":"Kim","year":"2023","journal-title":"Mult Scler J"},{"key":"10.1016\/j.dld.2026.04.018_bib0028","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.cgh.2019.03.027","article-title":"De Novo colitis associated with Rituximab in 21 patients at a tertiary center","author":"Eckmann","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2026.04.018_bib0029","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A protective function for interleukin 17A in T cell-mediated intestinal inflammation","volume":"10","author":"O\u2019Connor","year":"2009","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.dld.2026.04.018_bib0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/cpt.2155","article-title":"IL-17 inhibitors and inflammatory bowel diseases: a postmarketing study in Vigibase","volume":"110","author":"Petitpain","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.04.018_bib0031","article-title":"Secukinumab-induced lymphocytic colitis","volume":"10","author":"Gandu","year":"2022","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"9","key":"10.1016\/j.dld.2026.04.018_bib0032","first-page":"1131","article-title":"Emergence of inflammatory bowel disease during treatment with Secukinumab","volume":"12","author":"Fobelo Lozano","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2026.04.018_bib0033","unstructured":"Calmet F H, Yarur A J, Pukazhendhi G, Ahmad J, Bhamidimarri K R. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. vol. 28. 2015."},{"issue":"1","key":"10.1016\/j.dld.2026.04.018_bib0034","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.transproceed.2006.10.189","article-title":"Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?","volume":"39","author":"Arns","year":"2007","journal-title":"Transpl Proc"},{"key":"10.1016\/j.dld.2026.04.018_bib0035","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cgh.2024.08.026","article-title":"Update on the epidemiology and management of microscopic colitis","author":"Peery","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.04.018_bib0036","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cgh.2022.10.004","article-title":"Immune checkpoint inhibitor enterocolitis vs idiopathic inflammatory bowel disease","author":"Shirwaikar Thomas","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.04.018_bib0037","doi-asserted-by":"crossref","unstructured":"Gong Z, Wang Y. Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. vol. 16. 2020.","DOI":"10.1200\/OP.20.00002"},{"key":"10.1016\/j.dld.2026.04.018_bib0038","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2050640620951905","article-title":"European guidelines on microscopic colitis: united European Gastroenterology and European Microscopic Colitis Group statements and recommendations","author":"Miehlke","year":"2021","journal-title":"United Eur Gastroenterol J"},{"issue":"9","key":"10.1016\/j.dld.2026.04.018_bib0039","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/apt.16594","article-title":"Medication use and microscopic colitis","volume":"54","author":"Sandler","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.dld.2026.04.018_bib0040","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.16363","article-title":"Medication use and microscopic colitis: a multicentre retrospective cohort study","volume":"53","author":"Zylberberg","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dld.2026.04.018_bib0041","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.7326\/ANNALS-25-00268","article-title":"Medications and risk for microscopic colitis: a nationwide study of older adults in Sweden","volume":"178","author":"Khalili","year":"2025","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.dld.2026.04.018_bib0042","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The weber effect and the united states food and drug administration\u2019s adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"issue":"9450","key":"10.1016\/j.dld.2026.04.018_bib0043","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(04)17518-1","article-title":"Microscopic colitis: a missed diagnosis?","volume":"364","author":"Nielsen","year":"2004","journal-title":"Lancet"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:23:10Z","timestamp":1781652190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826007255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1590865826007255"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.018","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory therapies and emerging drug associations with microscopic colitis: A global pharmacovigilance analysis","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}